Indaptus Therapeutics
INDP
17 hedge funds and large institutions have $1.22M invested in Indaptus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more funds holding
Funds holding: 15 → 17 (+2)
0.03% more ownership
Funds ownership: 0.22% → 0.25% (+0.03%)
6% less capital invested
Capital invested by funds: $1.31M → $1.22M (-$83K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Strategy Asset Managers
Pasadena,
California
|
+$154K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$30.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.11K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$7.25K |
| 5 |
BSB
Bangor Savings Bank
Bangor,
Maine
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$7.71K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$5.14K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.82K |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$78 |
INDP Hedge Fund Activity: Q3 2022 in Review
17 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2022, worth a combined $1.22M — down 6.4% from $1.31M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new INDP positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Strategy Asset Managers, opening a new position worth an estimated $154K. The largest seller was Harel Insurance Investments & Financial Services, cutting an estimated $7.71K.
- 17 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2022, up from 15 in Q2 2022.
- Funds reported $1.22M of Indaptus Therapeutics stock for Q3 2022, down 6.4% quarter-over-quarter.
- 3 funds opened new Indaptus Therapeutics positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest Indaptus Therapeutics buyer in Q3 2022 was Strategy Asset Managers, an estimated $154K added.
- The largest Indaptus Therapeutics seller in Q3 2022 was Harel Insurance Investments & Financial Services, an estimated $7.71K sold.
Based on aggregated 13F filings for Q3 2022.